These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Strategies to Reduce the On-Target Platelet Toxicity of Bcl-x Negi A; Voisin-Chiret AS Chembiochem; 2022 Jun; 23(12):e202100689. PubMed ID: 35263486 [TBL] [Abstract][Full Text] [Related]
7. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D Cells; 2024 Mar; 13(6):. PubMed ID: 38534371 [TBL] [Abstract][Full Text] [Related]
8. Mivebresib synergized with PZ703b, a novel Bcl-xl PROTAC degrader, induces apoptosis in bladder cancer cells via the mitochondrial pathway. Xu Y; Lei Z; Zhu J; Wan L Biochem Biophys Res Commun; 2022 Oct; 623():120-126. PubMed ID: 35921705 [TBL] [Abstract][Full Text] [Related]
9. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. He Y; Koch R; Budamagunta V; Zhang P; Zhang X; Khan S; Thummuri D; Ortiz YT; Zhang X; Lv D; Wiegand JS; Li W; Palmer AC; Zheng G; Weinstock DM; Zhou D J Hematol Oncol; 2020 Jul; 13(1):95. PubMed ID: 32677976 [TBL] [Abstract][Full Text] [Related]
10. Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nayak D; Lv D; Yuan Y; Zhang P; Hu W; Nayak A; Ruben EA; Lv Z; Sung P; Hromas R; Zheng G; Zhou D; Olsen SK Nat Commun; 2024 Mar; 15(1):2743. PubMed ID: 38548768 [TBL] [Abstract][Full Text] [Related]
11. A selective BCL-X Khan S; Zhang X; Lv D; Zhang Q; He Y; Zhang P; Liu X; Thummuri D; Yuan Y; Wiegand JS; Pei J; Zhang W; Sharma A; McCurdy CR; Kuruvilla VM; Baran N; Ferrando AA; Kim YM; Rogojina A; Houghton PJ; Huang G; Hromas R; Konopleva M; Zheng G; Zhou D Nat Med; 2019 Dec; 25(12):1938-1947. PubMed ID: 31792461 [TBL] [Abstract][Full Text] [Related]
12. The PROTAC selectively degrading Bcl-x Zhang S; Chen Y; Xu Z; Yang J; Sun R; Wang J; Sun Y; Jiang B; Yang X; Tan W Theranostics; 2022; 12(17):7476-7490. PubMed ID: 36438482 [No Abstract] [Full Text] [Related]
13. Anti-apoptotic protein BCL-XL as a therapeutic vulnerability in gastric cancer. Wei Y; Zhang L; Wang C; Li Z; Luo M; Xie G; Yang X; Li M; Ren S; Zhao D; Gao R; Gong JN Animal Model Exp Med; 2023 Jun; 6(3):245-254. PubMed ID: 37271936 [TBL] [Abstract][Full Text] [Related]
14. PROTAC-mediated dual degradation of BCL-xL and BCL-2 is a highly effective therapeutic strategy in small-cell lung cancer. Khan S; Cao L; Wiegand J; Zhang P; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D bioRxiv; 2024 Mar; ():. PubMed ID: 38464204 [TBL] [Abstract][Full Text] [Related]
15. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. He Y; Zhang X; Chang J; Kim HN; Zhang P; Wang Y; Khan S; Liu X; Zhang X; Lv D; Song L; Li W; Thummuri D; Yuan Y; Wiegand JS; Ortiz YT; Budamagunta V; Elisseeff JH; Campisi J; Almeida M; Zheng G; Zhou D Nat Commun; 2020 Apr; 11(1):1996. PubMed ID: 32332723 [TBL] [Abstract][Full Text] [Related]
16. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Jia Y; Han L; Ramage CL; Wang Z; Weng CC; Yang L; Colla S; Ma H; Zhang W; Andreeff M; Daver N; Jain N; Pemmaraju N; Bhalla K; Mustjoki S; Zhang P; Zheng G; Zhou D; Zhang Q; Konopleva M Haematologica; 2023 Oct; 108(10):2626-2638. PubMed ID: 37078252 [TBL] [Abstract][Full Text] [Related]
17. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X Zhang X; Thummuri D; He Y; Liu X; Zhang P; Zhou D; Zheng G Chem Commun (Camb); 2019 Dec; 55(98):14765-14768. PubMed ID: 31754664 [TBL] [Abstract][Full Text] [Related]
18. Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands. Wang Z; He N; Guo Z; Niu C; Song T; Guo Y; Cao K; Wang A; Zhu J; Zhang X; Zhang Z J Med Chem; 2019 Sep; 62(17):8152-8163. PubMed ID: 31389699 [TBL] [Abstract][Full Text] [Related]
19. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320 [TBL] [Abstract][Full Text] [Related]
20. Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X Roy MJ; Vom A; Okamoto T; Smith BJ; Birkinshaw RW; Yang H; Abdo H; White CA; Segal D; Huang DCS; Baell JB; Colman PM; Czabotar PE; Lessene G J Med Chem; 2021 May; 64(9):5447-5469. PubMed ID: 33904752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]